Loading
Heart Failure With Preserved Ejection Fraction (HFPEF) / Elecoglipron / Heart Failure With Mildly Reduced Ejection Fraction (hfmref) · Phase 3 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 3 randomized controlled trial of elecoglipron versus placebo in adults with HFpEF or HFmrEF, powered to detect differences in cardiovascular death or HF hospitalization/urgent visit over up to 42 months. The registry record documents the protocol design; no outcome data are yet available, and recruitment has not started.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF); age from 18 Years. Intervention: Elecoglipron. Compared with: Placebo — Active Comparator. n = 6,950. 366 sites across 25 countries.
This is a planned Phase 3 randomized controlled trial of elecoglipron versus placebo in adults with HFpEF or HFmrEF, powered to detect differences in cardiovascular death or HF hospitalization/urgent visit over up to 42 months. The registry record documents the protocol design; no outcome data are yet available, and recruitment has not started.
No interim efficacy, safety, or outcome data are presented.
This trial is designed to address whether elecoglipron reduces cardiovascular death or HF hospitalization in HFpEF/HFmrEF patients. Results, when available, may inform treatment of these populations, but the evidence base does not yet exist in this registry record.
This is a registered Phase 3 trial that has not yet begun recruitment and reports no results; the evidence base is the study design itself, not outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This trial is designed to address whether elecoglipron reduces cardiovascular death or HF hospitalization in HFpEF/HFmrEF patients. Results, when available, may inform treatment of these populations, but the evidence base does not yet exist in this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07761117). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 6950 participants (ESTIMATED). Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF). Interventions: DRUG: Elecoglipron; DRUG: Placebo. Primary outcome measures: To evaluate the effect of elecoglipron compared with placebo in reducing the risk of CV death or HHF/urgent HF visit , Up to 42 months. Brief summary: This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.